share_log

Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings

Some Investors May Be Willing To Look Past Bio-Techne's (NASDAQ:TECH) Soft Earnings

一些投資者可能願意忽視bio-techne(納斯達克:TECH)的低收益
Simply Wall St ·  08/30 18:45

Shareholders appeared unconcerned with Bio-Techne Corporation's (NASDAQ:TECH) lackluster earnings report last week. We did some digging, and we believe the earnings are stronger than they seem.

上週,Bio-Techne Corporation(納斯達克股票代碼:TECH)的業績報告不佳,但股東們似乎並不擔心。我們做了一些調查,我們認爲這個業績比表面上看起來要強。

1725014702361
NasdaqGS:TECH Earnings and Revenue History August 30th 2024
納斯達克股票代碼:TECH的盈利和營業收入歷史數據截至2024年8月30日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

To properly understand Bio-Techne's profit results, we need to consider the US$39m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Bio-Techne to produce a higher profit next year, all else being equal.

爲了正確理解Bio-Techne的利潤結果,我們需要考慮到3900萬美元與非常規項目相關的費用扣除。雖然由於非常規項目的扣除而令人失望,但其中蘊含着一絲希望。我們研究了成千上萬家上市公司,發現非常規項目通常都是一次性的。這並不令人意外,因爲這些項目被認爲是非常規的。假設這些非常規費用不會再次出現,我們預計Bio-Techne在其他條件不變的情況下會在明年產生更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Bio-Techne's Profit Performance

我們對Bio-Techne的盈利表現的看法

Unusual items (expenses) detracted from Bio-Techne's earnings over the last year, but we might see an improvement next year. Because of this, we think Bio-Techne's earnings potential is at least as good as it seems, and maybe even better! And the EPS is up 18% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example - Bio-Techne has 1 warning sign we think you should be aware of.

飛凡在過去一年的營收中減少了一些異常項目(費用),但明年可能會有所改善。因此,我們認爲飛凡的盈利潛力至少與表面看起來一樣好,甚至可能更好!每股收益也已經連續三年增長18%。當然,在分析其盈利方面,我們只是剛剛開始;還可以考慮邊際、預測增長和投資回報率等其他因素。請記住,在分析股票時,值得注意涉及的風險。例如 - 飛凡有1個我們認爲您應該注意的警告信號。

This note has only looked at a single factor that sheds light on the nature of Bio-Techne's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這篇筆記只看了一個能揭示飛凡利潤性質的因素。但如果您能夠專注於細枝末節,就還有更多發現。有些人認爲高淨資產回報率是優質業務的良好跡象。雖然這可能需要您做一些研究,但您可能會發現這個擁有高淨資產回報率的公司的免費收藏或這個持有大量內部股份的股票清單會很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論